ELFN1

ELFN1 is a postsynaptic transmembrane leucine-rich repeat adhesion molecule expressed by defined subsets of hippocampal and cortical interneurons that organizes target-specific synaptic properties through retrograde transsynaptic signaling (PMID:23042292, PMID:24312227). It physically engages presynaptic group III metabotropic glutamate receptors in trans — binding mGluR4, mGluR6, mGluR7, and mGluR8 but not group I or II mGluRs — via its extracellular LRR/LRRCT module, which is necessary and sufficient for receptor binding and for ELFN1's own synaptic trafficking (PMID:29686062, PMID:40930976). At pyramidal→somatostatin interneuron synapses ELFN1 recruits and clusters mGluR7, driving glutamate-independent constitutive receptor activation that suppresses cAMP signaling by altering G protein activation kinetics, thereby setting a tonic low initial release probability and the characteristic facilitating behavior of these synapses (PMID:25047565, PMID:29686062, PMID:30940718). The interaction is bidirectional and stabilizing: N-glycosylation of the partner receptor (mGluR7 or mGluR6) is required for stable ELFN1 binding and surface localization, and reciprocally ELFN1 localization depends on its receptor partner, as shown by loss and rescue of rod-spherule ELFN1 in mGluR6-null retina (PMID:32931036, PMID:39681475, PMID:40930976). ELFN1 traffics to the membrane as an obligate LRR-mediated homodimer requiring a ~30-residue juxtamembranous intracellular motif (PMID:39675706). Loss-of-function variants that block ELFN1 surface trafficking cause a human neurodevelopmental disorder with epilepsy, recapitulated by seizures, hyperactivity, and motor abnormalities in Elfn1-null mice and zebrafish (PMID:25047565, PMID:40576023). ELFN1 also functions as a pharmacological context for mGluR7 modulator action, attenuating the maximal potentiation of mGluR7 positive allosteric modulators while preserving their activity at native synapses (PMID:40689847).

1. 2012 High

   Established that a postsynaptic interneuron-expressed molecule can dictate presynaptic release properties, defining a retrograde transsynaptic mechanism for building target-specific synapses.

   Evidence Cell-type-selective expression analysis plus loss-of-function in O-LM interneurons with electrophysiological readout of release probability

   PMID:23042292

   Open questions at the time

   • Molecular partner mediating the retrograde signal not yet identified
   • No biochemical interaction defined
2. 2013 Medium

   Mapped ELFN1 expression across interneuron and projection-neuron populations and demonstrated an in vivo requirement, linking its loss to seizures and behavioral abnormalities.

   Evidence β-galactosidase reporter knock-in expression mapping and behavioral phenotyping of knockout mice

   PMID:24312227

   Open questions at the time

   • Molecular mechanism of phenotype unresolved
   • Single lab
3. 2014 High

   Identified mGluR7 as the in-trans presynaptic partner that ELFN1 recruits, and connected the C-terminal recruitment region to human damaging mutations.

   Evidence Knockout mice, mGluR7 synaptic immunolocalization, presynaptic plasticity electrophysiology, and human mutation analysis

   PMID:25047565

   Open questions at the time

   • Binding determinants not yet mapped to specific ectodomain regions
   • Effect on receptor signaling not biochemically characterized
4. 2018 High

   Defined ELFN1 as a transsynaptic allosteric modulator with selectivity for all group III mGluRs and showed it directly reshapes G protein/cAMP signaling.

   Evidence Site-directed mutagenesis mapping two ectodomain binding sites; HEK293 transcellular reconstitution; BRET G protein kinetic assay

   PMID:29686062

   Open questions at the time

   • Structural basis of the LRR–mGluR interface not resolved
   • Reconstituted in heterologous cells rather than native synapses
5. 2019 High

   Demonstrated that ELFN1 drives constitutive, glutamate-independent mGluR7 activation by clustering, setting tonic low release probability at cortical pyr→SOM synapses.

   Evidence Cortical slice electrophysiology with pharmacological dissection and genetic loss-of-function for Elfn1 and mGluR7

   PMID:30940718

   Open questions at the time

   • Layer-specific contribution of GluK2-KARs versus mGluR7 not fully separated
   • How clustering produces constitutive activity mechanistically unclear
6. 2020 Medium

   Showed that receptor N-glycosylation is a prerequisite for ELFN1 binding, coupling mGluR7 maturation to stable transsynaptic complex formation.

   Evidence N-glycosylation site mutagenesis, fractionation, co-immunoprecipitation, and glycosylation inhibition in heterologous cells and neurons

   PMID:32931036

   Open questions at the time

   • Single lab
   • Direct structural role of glycans in the binding interface not defined
7. 2024 Medium

   Defined ELFN1 trafficking determinants, establishing that it reaches the membrane as an obligate LRR-mediated homodimer gated by a short intracellular motif.

   Evidence Domain deletion mutagenesis, biochemical fractionation, dimerization assays, and synaptic localization imaging

   PMID:39675706

   Open questions at the time

   • Functional consequence of ELFN1/ELFN2 heterodimerization in vivo unknown
   • Single lab
8. 2024 Medium

   Extended the glycosylation-dependent binding rule to mGluR6 and linked CSNB mutations to failed ELFN1 binding via defective Golgi glycosylation.

   Evidence Glycosylation analysis of mGluR6 CSNB mutants, co-IP with ELFN1, and bipolar cell immunolocalization

   PMID:39681475

   Open questions at the time

   • Single lab
   • Causality between glycosylation and binding shown correlatively in mutants
9. 2024 Low

   Provided experimental evidence that ELFN1 acts outside the nervous system, influencing fibroblast morphology and motility in ECM models.

   Evidence Patient-derived ELFN1-mutant skin fibroblasts in in vitro and decellularized ECM models

   PMID:38986898

   Open questions at the time

   • No molecular mechanism identified beyond loss of expression
   • Single patient-derived model, not independently replicated
10. 2025 Medium

    Localized the binding/trafficking function to the LRR-LRRCT module and demonstrated bidirectional mutual stabilization between ELFN1 and mGluR6 at rod spherules.

    Evidence ELFN1 deletion-construct binding assays, mGluR6-KO immunolocalization, and mGluR6-EGFP rescue in ON-bipolar cells

    PMID:40930976

    Open questions at the time

    • Single lab
    • Atomic structure of the LRRCT–mGluR interface not determined
11. 2025 Medium

    Confirmed ELFN1 loss-of-function as a Mendelian cause of neurodevelopmental disorder with epilepsy, tying the disease to defective ELFN1 surface trafficking.

    Evidence Whole-exome sequencing of multiple families, cell-surface trafficking assays, and Elfn1 KO mouse and zebrafish phenotyping

    PMID:40576023

    Open questions at the time

    • Genotype–phenotype correlations across variant classes incomplete
    • Single study
12. 2025 Medium

    Characterized how ELFN1 shapes the pharmacology of mGluR7 allosteric modulators, informing therapeutic targeting at native synapses.

    Evidence Transcellular mGluR7 signaling assays ± ELFN1 and slice electrophysiology at pyr→SOM synapses

    PMID:40689847

    Open questions at the time

    • Single lab
    • Therapeutic relevance in disease models not tested

• The atomic structure of the ELFN1 LRR/LRRCT–group III mGluR complex and the mechanism by which trans-binding converts to constitutive G protein modulation remain unresolved.
• No structural model of the binding interface
• Mechanistic link between clustering and constitutive receptor activity undefined
• Non-neuronal ECM role lacks molecular mechanism